Last reviewed · How we verify
NCT04388280: FIND
Imaging vs. no Testing in Asymptomatic High-risk Diabetic Patients
NA trial testing Echocardiography in Asymptomatic in 400 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Clinical Centre of Serbia |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 400 |
| Start date | 28 January 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Serbia |
Drugs / interventions tested
- Echocardiography
- CT angiography
Conditions studied
- Asymptomatic — all drugs for Asymptomatic →
- High Risk — all drugs for High Risk →
- Diabetes — all drugs for Diabetes →
Sponsor
Clinical Centre of Serbia
Who can join
Adults 30 to 80, any sex, with Asymptomatic or High Risk. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study was to evaluate 1- and 3-year outcome of alternative imaging strategies in asymptomatic high-risk diabetic patients: functional stress echocardiography combined with coronary flow reserve (CFR) and strain imaging, or computed tomography (CT) angiography with direct visualization of coronary arteries, and no testing at all.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04388280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Echocardiography
Trials testing the same drug.
- NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
- NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
- NCT06434064 — Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan · Phase 2 · recruiting
- NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
Other recruiting trials for Asymptomatic
Currently open trials in the same condition.
- NCT02933489 — Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts · NA · active not recruiting
Other Clinical Centre of Serbia trials
Trials by the same sponsor.
- NCT06570785 — IOPS Technology During Cannnulation of Contralateral Limb in EVAR · not yet recruiting
- NCT06253312 — Treatment of TASC C and D Aortoiliac Lesions · recruiting
- NCT05857202 — Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer · unknown
- NCT05116696 — Comparison of Outcomes of Patients With Stage IV Chronic Limb-threatening Ischemia and Colorectal Cancer · completed
- NCT04165629 — Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04388280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinical Centre of Serbia
- Last refreshed: 18 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04388280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing